Omega Healthcare Investors Q4 2025 Earnings Report

Omega Healthcare Investors EPS Results

• Actual EPS: N/A
• Consensus EPS: $0.79
• Beat/Miss: N/A
• One Year Ago EPS: $0.74

Omega Healthcare Investors Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $287.18 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Omega Healthcare Investors Announcement Details

• Quarter: Q4 2025
• Date: 2/4/2026
• Time: After Market Closes
• Conference Call Date: Thursday, February 5, 2026
• Conference Call Time: 10:00AM ET

Omega Healthcare Investors (NYSE:OHI) is a real estate investment trust (REIT) that specializes in the ownership and management of healthcare-related facilities. The company’s core business involves acquiring and leasing long-term care properties, including skilled nursing facilities and assisted living communities, under net lease agreements. Its portfolio is designed to provide stable, inflation-protected cash flows from operators responsible for day-to-day property management.

Founded in 1992 and headquartered in Hunt Valley, Maryland, Omega Healthcare Investors has grown its holdings to encompass hundreds of facilities across the United States, with a smaller presence in select international markets. The company focuses on sale-leaseback transactions and portfolio acquisitions, partnering with leading healthcare providers to expand or reposition their real estate. Its portfolio diversification by geography and operator credit quality aims to mitigate market concentration risk.

Omega Healthcare Investors is led by a management team with extensive experience in real estate investment, healthcare operations, and capital markets. The board and senior leadership oversee strategic capital allocation, asset acquisitions, and lease structuring to maintain a high-quality portfolio. Through disciplined underwriting and active asset management, the company seeks to deliver long-term growth and income to its shareholders.

Omega Healthcare Investors Q4 2025 Earnings Call Transcript

Key Takeaways

• Positive Sentiment: Q4 results — Omega reported adjusted FFO of $0.80 per share and FAD of $0.76, full-year AFFO/FAD grew >8%, dividend payout ratios fell to 84% (AFFO) and 88% (FAD), and 2026 AFFO guidance is $3.15–$3.25 per share.
• Positive Sentiment: Balance sheet — Management repaid >$700M of funded debt, reduced leverage to 3.51x, increased liquidity (new $2B ATM and ≈$1.7B revolver capacity) and says the capital stack is positioned to fund the active pipeline.
• Negative Sentiment: Genesis bankruptcy — Genesis (Chapter 11) remains unresolved; Omega leases 31 Genesis facilities ($52M annual rent) and holds a $129M term loan plus an $8M DIP commitment; a buyer was approved but the process may not conclude until Q3/Q4 2026 and timing/outcome remain uncertain despite management saying the loan appears fully secured.
• Positive Sentiment: Investment strategy and deals — Omega deployed ~$1.1B in 2025, expanded into RIDEA structures, materially increased its Saber relationship (real estate JV plus operating-company equity) and made a convertible Canadian development loan, signaling diversification toward higher risk-adjusted returns.
• Neutral Sentiment: Portfolio and regulatory trends — Trailing-12-month EBITDAR coverage rose to 1.57x and core occupancy is ~96–97%; Maplewood is paying cash flow and targeting high-single-digit rate increases, while proposed Medicare Advantage and staffing developments are being monitored but are expected to have limited near-term portfolio impact.

Presentation

[Operator]

Thank you for standing by. My name is Van, and I will be your conference operator today. At this time, I would like to welcome everyone to the Omega Healthcare Investors, Inc. Fourth Quarter Earnings Conference Call. All lines have been placed on mute to prevent any background noise, and after the speaker's remarks, there will be a question and answer session.

[Operator]

If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question, press star one again. Thank you. I would now like to turn the call over to Michele Reber. Please go ahead.

[Michele Reber, Head of Investor Relations at Omega Healthcare Investors]

Thank you, and good morning. With me today is Omega CEO Taylor Pickett, President Matthew Gourmand, CFO Bob Stephenson, CIO Vikas Gupta, and Megan Krull, Senior Vice President, Data Intelligence and Government Relations. Comments made during this conference call that are not historical facts may be forward-looking statements, such as statements regarding our financial projections, potential transactions, operator prospects, and outlook generally.

[Michele Reber, Head of Investor Relations at Omega Healthcare Investors]

Factors that could cause actual results to differ materially from those in the forward-looking statements are detailed in the company's filings with the SEC. During the call today, we will refer to some non-GAAP financial measures, such as NAREIT FFO, adjusted FFO, FAD, and EBITDA. Reconciliations of these non-GAAP measures to the most comparable measure under generally accepted accounting principles are available in the quarterly supplement.

[Michele Reber, Head of Investor Relations at Omega Healthcare Investors]

In addition, certain operator coverage and financial information that we discuss is based on data provided by our operators that has not been independently verified by Omega. I will now turn the call over to Taylor.

[Taylor C. Pickett, CEO at Omega Healthcare Investors]

Thanks, Michele. Good morning, and thank you for joining our Fourth Quarter 2025 Earnings Conference Call. Today, I will discuss our fourth quarter financial results and certain key operating trends. Fourth quarter adjusted funds from operations, AFFO, of $0.80 per share, and FAD, funds available for distribution of $0.76 per share, reflects strong revenue and EBITDA growth, principally fueled by acquisitions and active portfolio management.

[Taylor C. Pickett, CEO at Omega Healthcare Investors]

Our dividend payout ratio has dropped to 84% for AFFO and 88% for FAD. 2025 was a great year for our team. Full year AFFO and FAD growth exceeded 8% year-over-year, driven in part by $1.1 billion in capital deployment. In addition, the credit quality of our operators continued to improve as a result of active portfolio management and the overall improvement in industry fundamentals.

[Taylor C. Pickett, CEO at Omega Healthcare Investors]

During the fourth quarter, we closed two RIDEA transactions totaling $80 million. We significantly expanded our Saber relationship, and we committed capital in Canada. All this while de-levering and strengthening the balance sheet. Our momentum from 2025 should carry us forward for another strong year in 2026.

[Taylor C. Pickett, CEO at Omega Healthcare Investors]

We will continue to actively manage and enhance the credit quality of our operating relationships. We will continue to deploy meaningful capital across all of our geographies and property types, including our new RIDEA platform. It is likely by year-end that Saber will be our largest source of revenue. Furthermore, by year-end, it is likely that we will have the strongest tenant credit profile and balance sheet in Omega's history. I will now turn the call over to Vikas.

[Vikas Gupta, CIO at Omega Healthcare Investors]

Thank you, Taylor, and good morning, everyone. Today, I will discuss the most recent performance trends for Omega's operating portfolio, including an update on Genesis, as well as Omega's investment activity for 2025, including fourth quarter and subsequent closings. We'll also give an update on Omega's pipeline and market trends for 2026.

[Vikas Gupta, CIO at Omega Healthcare Investors]

Turning to portfolio performance. Omega has investments in 1,111 facilities, consisting of 1,027 in our owned real estate and mortgage loan portfolio, and 84 facilities in joint ventures with operating partners and third-party real estate investors. Of the total number of facilities, 62% are skilled nursing and transitional care facilities, and 38% are U.S. senior housing and U.K. care homes.

[Vikas Gupta, CIO at Omega Healthcare Investors]

Trailing 12-month operator EBITDAR coverage for our triple net and mortgage core portfolio as of September 30, 2025, increased to 1.57x compared to our second quarter 2025 reported coverage of 1.55x. Core portfolio coverage continues to trend in a favorable direction, above industry average coverage levels, and as discussed in prior quarters, provides us with confidence that our operating partners have sufficient means to provide superior clinical service to residents.

[Vikas Gupta, CIO at Omega Healthcare Investors]

In addition to the strong credit support this provides for existing investments, these coverage levels enable Omega and our operating partners to continue to grow our respective businesses. As reported previously, Genesis filed for Chapter 11 bankruptcy protection in July 2025. As a reminder, Omega leases Genesis 31 facilities for annual rent payments of $52 million. Our coverage continues to be above the mean coverage for our entire portfolio.

[Vikas Gupta, CIO at Omega Healthcare Investors]

Additionally, Omega has a $129 million piece of a term loan with Genesis, which is secured by a first lien on essentially all of the assets of Genesis other than the AR, on which we have a second lien. We believe that the loan is fully secured. While the Unsecured Creditors Committee has challenged the value of the loan collateral, among other things, as part of the proceeding, we believe these arguments are without merit.

[Vikas Gupta, CIO at Omega Healthcare Investors]

Based on our lease coverage and collateral, we believe our credit position in this portfolio is strong. The bankruptcy process is progressing with a few critical events taking place in the last few weeks, including a second auction of the Genesis assets and a related sale approval hearing.

[Vikas Gupta, CIO at Omega Healthcare Investors]

Per the judge's order, after the results of the first auction of Genesis assets were not approved in November 2025, a second auction was held on January 13th, and the winning bidder was a group known as 101 West State Street. This group's bid was approved by the bankruptcy court on January 26th. The principals of 101 West State Street currently operate approximately 60 facilities on the West Coast.

[Vikas Gupta, CIO at Omega Healthcare Investors]

As required, they have submitted a hard deposit of $54 million and have an aggregate of 85 days, inclusive of additional hard deposits needed for extensions, to represent that they have procured market financing commitments, which, with contributed equity, satisfies the cash portion of its bid. As previously reported, Omega committed to support Genesis by providing $8 million of a total $30 million debtor-in-possession loan. Genesis continues to pay us full contractual rent each month since filing bankruptcy.

[Vikas Gupta, CIO at Omega Healthcare Investors]

Due to the delays that came with having a second auction, the bankruptcy process is now anticipated to conclude in Q3 or Q4 of 2026. If 101 West State Street consummates its purchase of the Genesis Healthcare assets, Omega anticipates that it will assume our lease, and the cash proceeds of the sale will be sufficient to cover the payment in full of our DIP loan and term loan.

[Vikas Gupta, CIO at Omega Healthcare Investors]

These assumptions and timeline, along with all elements of the bankruptcy process, are subject to further developments in events in the bankruptcy proceeding, and we cannot be certain of the outcome. There are no material open issues with any other large operators. Turning to new investments. Omega's transaction activity in 2025 was very strong, with over $1.1 billion in new investments.

[Vikas Gupta, CIO at Omega Healthcare Investors]

These transactions varied in size and nature, but demonstrate Omega's ability to adapt to the evolving investment landscape in the long-term care industry. In 2025, we continued to support the growth of our existing and new operators by focusing on strong credit-backed real estate and also closed on our first RIDEA transactions in the U.S. senior housing space.

[Vikas Gupta, CIO at Omega Healthcare Investors]

Of our total $1.1 billion in new investments, a little over $700 million, or approximately 66%, was in senior housing facilities or U.K. care homes. Although we continue to invest in the U.S. skilled nursing sector to support and partner with best-in-class operators such as Saber, this demonstrates how we are focusing on all asset classes and deal structures to maximize returns for our shareholders.

[Vikas Gupta, CIO at Omega Healthcare Investors]

As Matthew discussed on our last call, our primary goal is to allocate capital with a focus on growing FAD per share on a risk-adjusted basis. Accordingly, we have expanded our investment structures to now include RIDEA for U.S. senior housing and U.K. care homes, with the goal of achieving higher risk-adjusted returns over time.

[Vikas Gupta, CIO at Omega Healthcare Investors]

We believe we are well positioned to enhance shareholder returns by acquiring underperforming assets at prices meaningfully below replacement cost, and then partnering with proven operators to enhance the cash flow and underlying real estate value of such assets. Our target return for our investments is an unlevered IRR of at least low- to mid-teens, not assuming any cap rate compression upon exit in our underwriting. During the fourth quarter of 2025, Omega completed a total of $334 million in new investments, not including $31 million in CapEx.

[Vikas Gupta, CIO at Omega Healthcare Investors]

These new investments included the previously announced Saber JV real estate transaction, U.S. senior housing RIDEA transactions, and various other real estate investments in the U.S. and the U.K. For our new RIDEA investments, we acquired 4 senior housing facilities located in New Jersey, Wisconsin, and Indiana for $37 million.

[Vikas Gupta, CIO at Omega Healthcare Investors]

We have engaged two third-party managers to operate the facilities on our behalf. Additionally, we made a $43 million investment for a 49% equity interest in a Class A rental CCRC in North Carolina, which will also operate via a RIDEA structure. Our other fourth quarter investments included the purchase of a U.K. care home for $16 million and $16 million in real estate loans. These additional investments were at a rate of 10%, and the real estate loans have an option for Omega to realize upside upon a refinance or sale of the facilities.

[Vikas Gupta, CIO at Omega Healthcare Investors]

Subsequent to quarter end, Omega closed on $212 million of additional investments. As previously announced and anticipated, on January 1st, Omega closed on the purchase of 9.9% of the equity interest in Saber's operating company for $93 million. Omega will receive a minimum 8% cash return on our investment.

[Vikas Gupta, CIO at Omega Healthcare Investors]

Cash flow from the Saber operating company is anticipated to support a greater payment, but cash will be retained for Saber's growth, and all additional amounts due to Omega will be accrued. As a reminder, this was step two of our overall investment in Saber, where step one was our $222 million dollar real estate investment for a 49% equity interest in 64 facilities operated by Saber. The completion of our investment in the Saber operating company creates strong alignment between Omega and Saber.

[Vikas Gupta, CIO at Omega Healthcare Investors]

With our geographic scope and capital and Saber's operational expertise, we collectively are in a unique position to evaluate growth opportunities and have optionality for deal structures, including our triple net master lease, the Saber-Omega Real Estate Joint Venture, and the Saber operating company. We're actively evaluating additional opportunities to grow the Saber-Omega relationship.

[Vikas Gupta, CIO at Omega Healthcare Investors]

Also, subsequent to quarter end, Omega closed on the purchase of 13 skilled nursing facilities located in Georgia for $109 million and one senior housing facility in Alabama for $10.3 million. The skilled nursing facilities will be leased to a current Omega operator at a lease yield of 10.6%, and the senior housing facility will be operated by Omega and managed by a third-party manager via a RIDEA structure.

[Vikas Gupta, CIO at Omega Healthcare Investors]

Lastly, we are proud to announce that we have closed on a commitment to fund up to $64 million for the development of five replacement long-term care facilities in Ontario, Canada. The loan has a current pay interest rate of 10% and that Omega's option is convertible to a 34.9% equity stake in the borrower entity that owns 21 facilities.

[Vikas Gupta, CIO at Omega Healthcare Investors]

Omega's collateral for the loan is this entire 21 facility portfolio, valued today at over $130 million. Based on the credibility of our development and operating partner, the strong collateral for the loan, the wait list for long-term care facilities driven by demographics, and the overall support of the Canadian government for the long-term care sector in Ontario, we believe this is a good risk-adjusted opportunity for our initial entry into Canada. Turning to the pipeline.

[Vikas Gupta, CIO at Omega Healthcare Investors]

Similar to 2025, our pipeline for 2026 is strong. Marketed opportunities both in the U.S. and the U.K. continue to be substantial, and we continue to see off-market opportunities through our operating partners, including our new RIDEA partners and managers. We continue to focus on growing our Rolodex of potential operating partners. As we've done for the past two decades, our relationships are a key component to our growth.

[Vikas Gupta, CIO at Omega Healthcare Investors]

As mentioned earlier, we continue to evaluate and focus on purchasing U.S. skilled nursing facilities, U.S. senior housing facilities, and U.K. care homes, with increased flexibility on deal structures ensure that Omega and its shareholders are able to benefit from additional sources of income, whether that be through variations on triple net lease structures, RIDEA for senior housing assets, or U.K. care homes, or strategic joint ventures. I will now turn the call over to Bob.

[Bob Stephenson, CFO at Omega Healthcare Investors]

Thanks, Vikas, and good morning. Turning to our financials for the fourth quarter of 2025. Revenue for the fourth quarter was $319 million, compared to $279 million for the fourth quarter of 2024. The year-over-year increase is primarily the result of the timing and impact of revenue from net new investments completed throughout 2024 and 2025. Our net income for the fourth quarter was $172 million, or $0.55 per common share, compared to $116 million, or $0.41 per common share for the fourth quarter of 2024.

[Bob Stephenson, CFO at Omega Healthcare Investors]

Our Adjusted FFO was $250 million, or $0.80 per share for the quarter, and our FAD was $238 million, or $0.76 per share, and both exclude several items outlined in our NAREIT FFO, adjusted FFO, and FAD reconciliations to net income found in our earnings release, as well as our fourth quarter financial supplemental posted to our website.

[Bob Stephenson, CFO at Omega Healthcare Investors]

Our fourth quarter 2025 FAD was one penny greater than our third quarter FAD, with the increase primarily resulting from incremental revenue related to the timing and completion of $485 million in new investments during the third and fourth quarters. Incremental Maplewood revenue, as they paid $18.9 million in Q4, an increase of $200,000 compared to Q3.

[Bob Stephenson, CFO at Omega Healthcare Investors]

Lower net interest expense of approximately $1 million, resulting from bond and term loan payoffs in the fourth quarter. These were partially offset by $100 million in asset sales and $61 million in loan repayments over the past two quarters, resulting in a $2.1 million reduction to the fourth quarter FAD, coupled with the issuance of a combined 7.8 million common shares of stock and OP units over the past two quarters to fund new investments.

[Bob Stephenson, CFO at Omega Healthcare Investors]

Our balance sheet remains incredibly strong as we continued to take steps to improve our liquidity capital stack maturity ladder. In the fourth quarter, we funded $334 million of new investments, primarily by issuing 5.5 million Omega operating partnership units, valued at $222 million.

[Bob Stephenson, CFO at Omega Healthcare Investors]

Additionally, in the fourth quarter, we reduced our funded debt by over $700 million as we repaid $600 million of senior unsecured notes, repaid a GBP 183 million pound sterling secured mortgage loan, and repaid the $428.5 million term loan, all prior to their scheduled maturity dates. All three pieces of debt were repaid utilizing a combination of balance sheet cash, our revolver, and fully borrowing on the $300 million delayed draw term loan.

[Bob Stephenson, CFO at Omega Healthcare Investors]

Our next scheduled maturity is in April 2027. In the fourth quarter, we also improved our liquidity as we entered into a new $2 billion ATM program. At December 31, we ended the quarter with $27 million in available cash on the balance sheet and over $1.7 billion of available capacity under our $2 billion revolver.

[Bob Stephenson, CFO at Omega Healthcare Investors]

Our fixed charge coverage ratio was 5.8x, and our leverage was further reduced to 3.51x. We are excited as our balance sheet and cost of capital continue to position us to approvingly fund our active pipeline. Turning to guidance. As Taylor mentioned, our momentum from 2025 should carry us forward for another strong year in 2026.

[Bob Stephenson, CFO at Omega Healthcare Investors]

We are providing full year Adjusted FFO guidance of a range between $3.15-$3.25 per share, which includes the assumptions outlined in our press release issued yesterday. I'd like to take a moment to highlight a few of the guidance assumptions. It includes the impact of the new investments completed as of February 4th and does not include any additional investments not outlined in our press release.

[Bob Stephenson, CFO at Omega Healthcare Investors]

It includes the impact of scheduled loan repayments and potential asset sales. Of the $213 million in mortgages and other real estate loans that are scheduled to mature in 2026, it assumes $157 million will be repaid, and the balance will be converted to fee simple real estate. Similarly, of the $267 million in non-real estate-backed loans that are scheduled to mature in 2026, it assumes $196 million will be repaid during 2026, which includes $137 million in Genesis loans, with the balance of the loans being extended beyond 2026.

[Bob Stephenson, CFO at Omega Healthcare Investors]

As I stated on our third quarter earnings call, we are always pruning and strengthening our portfolio through asset sales, and our initial 2026 guidance includes approximately $15 million-$25 million per quarter in asset sales.

[Bob Stephenson, CFO at Omega Healthcare Investors]

The high end of the range in our guidance includes, but is not limited to, additional cash from Maplewood, as well as other cash-based operators, timing or potential extension of loan repayments and asset sales, GNA at the lower end of the range, to name a few. Our 2026 adjusted FFO guidance does not include any additional investments or additional capital market transactions, other than what I just mentioned, or what was included in the earnings release. I will now turn the call over to Megan.

[Megan Krull, Senior Vice President, Data Intelligence and Government Relations at Omega Healthcare Investors]

Thanks, Bob, and good morning, everyone. Last quarter, I mentioned the potential for an automatic 4% cut to Medicare related to the deficit caused by the OBBA. Since then, the automatic reduction has been dealt with legislatively, as has historically been the case, and is therefore no longer an issue.

[Megan Krull, Senior Vice President, Data Intelligence and Government Relations at Omega Healthcare Investors]

Additionally, in December, HHS officially repealed the minimum staffing standards through an interim final rule, an action that we applaud as the draconian nature of the rule stood to make the provision of and access to care more difficult. Moving forward, we hope that this administration, who has been so supportive of this industry, will work with industry leaders to find other ways to obtain regulatory rationalization going into 2026.

[Megan Krull, Senior Vice President, Data Intelligence and Government Relations at Omega Healthcare Investors]

Additionally, while Medicare Advantage has been a topic of conversation over the last week, with CMS proposing relatively flat rates in 2027, despite rising healthcare costs, I think it is important to point out that the impact to our portfolio would be minimal if implemented as proposed.

[Megan Krull, Senior Vice President, Data Intelligence and Government Relations at Omega Healthcare Investors]

Not only are our current coverages, as noted earlier by Vikas, able to withstand a certain level of expense pressure in the face of reimbursement not keeping pace, the percentage of our operator's revenue associated with Medicare Advantage is low. With total Medicare accounting for less than 26.1% of overall operator revenue when excluding non-Medicare quality mix, and a Medicare Advantage penetration arguably far less than the 50% plus you see in the overall Medicare population, only a small portion of the business is impacted by this news.

[Megan Krull, Senior Vice President, Data Intelligence and Government Relations at Omega Healthcare Investors]

While we are unconcerned with this latest development, we are still carefully watching state reactions to the OBBA, as well as the impact it may have on the overall health of our operators' referral sources. We continue to support the efforts of our operators, partners, and industry associations in educating lawmakers, both at the federal and state levels, on the importance of the services provided by the long-term care industry and the need to fund it appropriately. I will now open the call up for questions.

[Operator]

At this time, I would like to remind everyone in order to ask a question, press star, then the number one on your telephone keypad. Please limit your questions to one and one follow-up. Your first question comes from the line of Seth Canetto-Dougherty from Citi. Please go ahead.

[Nick Joseph, Head of US Real Estate and Lodging Research at Citi]

Thanks. It's Nick Joseph here with Seth. I just wanted to dive in a little to the Saber strategy and kind of curious how you think of it, being differentiated versus peers, and the ability to grow, just given the competition and the capital that has been moving into that space.

[Matthew Gourmand, President at Omega Healthcare Investors]

Sure, Nick, it's Matthew here. So I think the differentiation, as much as anything, is on two or three different fronts. Number one, we are looking at smaller deals, tend to be relatively rifle shot deals as opposed to larger portfolio deals.

[Matthew Gourmand, President at Omega Healthcare Investors]

You tend to find a little bit better economics in that situation. I would say a lot of the deals we're looking at are deals that need a little bit of love, a little bit of turnaround, either lower occupancy, lower margin. We're aligning with operators who have expertise in that specific area, be it the asset class that we're looking at and the region that we're looking at, and have demonstrated the ability to turn around facilities like that.

[Matthew Gourmand, President at Omega Healthcare Investors]

So I think, you know, we're much more looking for the, as Vikas said in his talking points, the low- to mid-teens IRRs, and the only real way to obtain that, is taking assets that need a, a little bit more of a turnaround opportunity. And then, obviously, we've structured the promotes as everyone tries to, to align our interests with, those of our managers, to make sure that they are sufficiently incentivized to obtain the, the financial returns that we're looking to achieve.

[Nick Joseph, Head of US Real Estate and Lodging Research at Citi]

That's very helpful. Thank you. As you think about kind of the turnarounds for those assets, do you assume that occupancy goes down initially, or how do you underwrite at least the initial years of performance of those facilities?

[Matthew Gourmand, President at Omega Healthcare Investors]

Sure. I mean, it's a case-by-case basis, it's gonna be determined on what we think needs to get done within those facilities, the ability of the former manager to market those effectively, the ability to push rate. That each one is very idiosyncratic, but needless to say, we spend a lot of time really understanding and scrubbing the reality of those numbers and the viability of those numbers to make sure that we're conservatively underwriting.

[Nick Joseph, Head of US Real Estate and Lodging Research at Citi]

Thank you.

[Matthew Gourmand, President at Omega Healthcare Investors]

Thanks.

[Operator]

Our next question comes from the line of Omotayo Okusanya from Deutsche Bank. Please go ahead.

[Omotayo Okusanya, Managing Director, Head of US REIT Research at Deutsche Bank]

Hey, guys. Yeah, this is Sam on for Tayo. I was wondering if you guys can give any update on PAX? Like, do you guys have any insight around the outcome of the federal investigation?

[Vikas Gupta, CIO at Omega Healthcare Investors]

Yeah, and this is Vikas. No, we don't have any more info on the investigation than what the public knows. I will say we continue to be in close touch with the PACS management team. Their buildings continue to perform strongly here at Omega. Good credit, good operating results, and good clinical performance. So right now, we feel generally good about it at Omega.

[Omotayo Okusanya, Managing Director, Head of US REIT Research at Deutsche Bank]

I guess my follow-up would be around Genesis. I guess, how should we think about the timing and expected returns on the redeployment of proceeds from Genesis-related loans in 2026?

[Bob Stephenson, CFO at Omega Healthcare Investors]

Yeah, this is Bob. In the guidance, what we're assuming is sometime mid-year, the loans, I said $137 million, that's made up of the combination of $8 million for the DIP and $129 million of what was on our balance sheet at 12/31. When we receive that back in, we will first pay off any balance that's on the credit facility, and the balance of that then will be invested roughly 3.5% our overnight rates.

[Omotayo Okusanya, Managing Director, Head of US REIT Research at Deutsche Bank]

Got it. Okay, thank you. That's all I got, guys. Appreciate the time.

[Operator]

Our next question comes from the line of Michael Goldsmith from UBS. Please go ahead.

[Michael Goldsmith, US REITs Analyst at UBS]

Good morning. Thanks for taking my questions. First, I wanted to ask for some color on the Georgia Skilled Nursing portfolio, just given this a little bit of a higher initial yield at 10.6% than we've seen in the U.S. of late. Is that pricing more of a function of having some hair on it or maybe more of a reflection of off-market deal flow? And am I reading it right that the facilities were transitioned to one of your existing operators from a prior operator?

[Vikas Gupta, CIO at Omega Healthcare Investors]

Yeah, Michael, this is Vikas. So, just for some guidance, we are still quoting 10% for all SNF deals today. This deal was an off-market deal, and we were able to achieve slightly higher. Nothing super hairy about it. Good buildings in Georgia, and yes, we are leasing this to a current Omega operator.

[Michael Goldsmith, US REITs Analyst at UBS]

Got it. Just as a follow-up here, historically, acquisition volume upside tends to come from the portfolio transaction. So how does the outlook for portfolios look right now? Are you seeing portfolios trade, and if so, are they trading at a premium or a discount? Thanks.

[Matthew Gourmand, President at Omega Healthcare Investors]

Sure. This is Matthew. They're trading, to the extent that they do trade, they're trading, at a premium, both on the skilled nursing and the seniors housing side of things and, and in the U.K. care homes. So there's, there's not many chunky deals that we're seeing out there right now, but to the extent that they have traded over the last 6-12 months, we have tended to see a little bit of a premium there.

[Matthew Gourmand, President at Omega Healthcare Investors]

Candidly, we'd rather choose selectively the facilities that we're looking to buy, and so particularly when you're paying a premium for those, those larger deals, they're not particularly attractive to us, but we obviously continue to look at everything.

[Michael Goldsmith, US REITs Analyst at UBS]

Got it. Thank you very much. Good luck in 2026.

[Matthew Gourmand, President at Omega Healthcare Investors]

Thank you.

[Operator]

Our next question comes from the line of Julian Blouin from Goldman Sachs. Please go ahead.

[Julien Blouin, Vice President, Real Estate Global Investment Research at Goldman Sachs]

Yeah, thank you for taking my question. Just regarding maybe the acquisitions that were closed in the fourth quarter and subsequent to quarter end, can you give us a sense of how those were sourced? Were they mostly on or off market? And then, what were the motivations of the sellers? I know you mentioned some turnarounds, so were these deals sort of mostly distressed situations?

[Vikas Gupta, CIO at Omega Healthcare Investors]

Yeah, just looking at the deals quickly, it, it's really a mixed bag. Some were marketed, some were not marketed. I, I will say there are quite a few that are off-market that came through current relationships. The most notable, of course, being the Saber deal. And then the second question was?

[Julien Blouin, Vice President, Real Estate Global Investment Research at Goldman Sachs]

What the motivation, seller motivation was.

[Vikas Gupta, CIO at Omega Healthcare Investors]

I mean, it's again a mixed bag. Some of it is liquidity, some of it is exiting. There are some turnarounds here, where we have put in new operators, such as the Georgia transaction. So once again, that's a mixed bag as well.

[Julien Blouin, Vice President, Real Estate Global Investment Research at Goldman Sachs]

Got it. Okay, thank you. And then, your tenant coverage, you mentioned, you know, continues to rise. It's the highest, I think, in recent history. Do you feel like at these coverage levels, you're approaching sort of coverage levels where you might be able to release that sort of positive spreads in future years? I know there's not much expiring this year, but a little bit more in 2027. Or is it really more that it just sort of increases the likelihood of renewal upon expiration?

[Matthew Gourmand, President at Omega Healthcare Investors]

Yeah, unfortunately, it's much more the latter. The majority of our leases have renewal options unilaterally at the right of the tenant. So even though it might show that it's expiring in 2027, to your point, if they're covering well, the likelihood is they will exercise that option to renew, and therefore, the opportunity for incremental pickup in the near term is relatively limited.

[Matthew Gourmand, President at Omega Healthcare Investors]

But obviously, as we continue to look out, eventually, these second and third renewal options, it tends to normally be a couple of renewal options, will also expire, and that pickup will be opportunistic for us. However, we don't see anything in the next three or four years that's gonna meaningfully move the needle on that front.

[Julien Blouin, Vice President, Real Estate Global Investment Research at Goldman Sachs]

Okay. Thank you.

[Operator]

Our next question comes from the line of Nick Yulico from Scotiabank. Please go ahead.

[Elmer Chang, Equity Research Associate at Scotiabank]

Hi. Thanks, this is Elmer Zhang, I'm with Nick. Considering guidance assumes rental payments at the current run rate... Is it reasonable to assume, Maplewood returns to the contractual rate by year-end? Because I think based on the improvement in rent payments in recent quarters, maybe there is some expectation they would be at contractual rent, by this quarter.

[Vikas Gupta, CIO at Omega Healthcare Investors]

Yeah, as we've said previously, Maplewood is paying us all their cash flow now. So as Bob discussed, we are getting a run rate of $76 million right now, and we assume that number will increase at a small level later this year.

[Matthew Gourmand, President at Omega Healthcare Investors]

Yeah, we don't really look at it so much in terms of contractual at this point. At the end of the day, they're going to continue to pay the cash flow. They obviously have some interest expense as well, that is due above and beyond their contractual rent obligations.

[Matthew Gourmand, President at Omega Healthcare Investors]

So as they continue to improve, and they've demonstrated a really decent ability to improve and enhance their cash flows over the last few years, and the management team is operating as well as any management team that we've seen out there right now. We will continue to benefit from that cash flow, but we don't look at it from a standpoint of contractual rent. We just look at it from a standpoint of a more like a RIDEA-like model at this point in time.

[Elmer Chang, Equity Research Associate at Scotiabank]

Right. Okay, thanks. Maybe second question is, how should we think about the cadence and potentially earnings impact of loan repayments this year and even in 2027 outside of the Genesis loans, just given the volume of investments you've done in the last couple of years?

[Matthew Gourmand, President at Omega Healthcare Investors]

Sure. This is Matthew again. Yeah, the loan repayments it's tough to model. Bob's obviously given guidance as to what we think in 2026. Loans are not a large portion of our overall business, but, you know, they do represent a little bit of a headwind to the extent that they do come back. I don't think it's going to be a meaningful headwind over the longer term.

[Matthew Gourmand, President at Omega Healthcare Investors]

Obviously, we have fairly pronounced amount of stuff potentially coming back in 2026 that we've highlighted. But longer term, it obviously creates a little bit of a headwind until we are able to redeploy the capital. But with the market being relatively robust today in terms of opportunities to deploy that capital, I don't think it's a long-term headwind for the company.

[Elmer Chang, Equity Research Associate at Scotiabank]

Okay, thank you.

[Operator]

Our next question comes from the line of John Kilichowski from Wells Fargo. Please go ahead.

[John Kilichowski, Executive Director Equity Research at Wells Fargo]

Hi, good morning, team. Maybe just to go back to Maplewood here. With the core portfolio well occupied, what are you seeing in terms of rent for export? What can you kind of disclose about the success of really driving the economics there? I'm just curious about... I understand you, you're not too focused on timeline to full rent, but just sort of helpful to think about what's the growth of that existing portfolio.

[Vikas Gupta, CIO at Omega Healthcare Investors]

Yeah. Hey, John, this is Vikas. Just some stats for you here. The Second Avenue building is now at 97%, and the overall core portfolio is at 96%. And, you know, as for growth, it's a lot of it's going to be driven by rate increases. Maplewood is shooting to do a single-digit percentage, a high single-digit percentage increase this year. We still don't know what that's going to be net, but that will, that will drive some growth, and we plan that will happen going forward in the years to come.

[John Kilichowski, Executive Director Equity Research at Wells Fargo]

Okay, very helpful. Thanks, Vikas. And then just to stay on Maplewood here. For Embassy Row, I don't know what else you can talk about here, but is there a—there's a JV partner in the OpCo, correct? And are you able to give any guidelines around maybe the remaining capital availability from them and helping make those yield on cost payments? I'm just curious, sort of, the—what's the lease-up trajectory and sort of timeline that needs to take place at Embassy Row, such that you wouldn't need to pull, let's say, capital from the outperformance on the core portfolio to make whole the yield on cost payments.

[Matthew Gourmand, President at Omega Healthcare Investors]

So I would say that, we actually, for the, for the first month, we've seen a positive cash flow, on that facility, at the end of last year, which is great. That's obviously prior to paying any rent. The lease-up is going in accordance with our expectations.

[Matthew Gourmand, President at Omega Healthcare Investors]

I think Maplewood is extremely focused on, on ensuring that, that doesn't create too much of a headwind for their overall portfolio performance. It, it's tough to say, you know, when you're in lease-up, what that, what that looks like. We look at it holistically over the context of the overall portfolio, and as Bob's indicated, we expect a modest pickup in February, and, and, and an ability to continue to pay that rate going forward.

[Matthew Gourmand, President at Omega Healthcare Investors]

But it's just too early to tell, both in the lease-up of that building and in the rate increases that they're trying to push across the portfolio right now, what that's going to look like on a consolidated basis.

[John Kilichowski, Executive Director Equity Research at Wells Fargo]

Got it. Thank you very much. Congrats on the quarter.

[Matthew Gourmand, President at Omega Healthcare Investors]

Thanks.

[Operator]

Our next question comes from the line of Juan Sanabria from BMO Capital Markets. Please go ahead.

[Juan Sanabria, Managing Director at BMO Capital Markets]

Hi, good morning. Just, on the shop investments, just curious, I know you talked about unlevered yields, but for the stuff you've done fourth quarter and year to date here, just curious on the initial yields and how we should be modeling the returns on that capital. And then... And as part of that, can you talk a little bit about the CapEx assumptions and maybe just give a little color on how we should think about FAD relative to adjusted FFO, from a guidance perspective for the full year?

[Taylor C. Pickett, CEO at Omega Healthcare Investors]

Yeah, I'll take the first part. Juan, it's Taylor. We're purposefully not disclosing initial yields because they're all over the place. We would have deals in the pipeline that have sh-- you know, high single digit yields right out of the box, we have some that are lower.

[Taylor C. Pickett, CEO at Omega Healthcare Investors]

It all goes back to what Matthew said, every deal is idiosyncratic, and we're looking at long-term IRRs, and we're not aggressive in terms of how we underwrite to get to those. So we feel really good about what we're finding and the operators we're putting these buildings in the hands of the bidder operator's hands where these buildings are going. And that's probably all I can say about it. In terms of CapEx, do you want to take that?

[Matthew Gourmand, President at Omega Healthcare Investors]

Yeah. So again, it's again a little bit of a mixed bag one. Some of the facilities we've picked up really don't need a lot of initial CapEx. Other ones probably do need a little TLC. That's a little bit of the nature of the turnaround element. We tend to price that in initially within our expectations.

[Matthew Gourmand, President at Omega Healthcare Investors]

And I would say that the yields that we're always quoting to you are yields that we think are sustainable after a decent CapEx assumption, either from an initial investment standpoint or even from a recurring standpoint. I don't know what that does in terms of how that looks for our AFFO relative to our FAD going forward, but we are primarily focused on just growing that FAD.

[Juan Sanabria, Managing Director at BMO Capital Markets]

Just with, like, regards to the 26 earnings guidance, how should we think about the delta between FAD and adjusted FFO?

[Bob Stephenson, CFO at Omega Healthcare Investors]

Well, typically, remember. Yeah, you're right. We only give AFFO guidance, but escalators will impact that as it goes along. But same with FAD, you got to remember that the asset sales and the repayment of the loan maturities also will impact that. So I would keep about the same relationship.

[Matthew Gourmand, President at Omega Healthcare Investors]

Yeah, I think the ratio—I mean, you have to remember, you know, we're a $14 billion company, and we just started investing in our idea. So I, I think that the ratio that you've seen between AFFO and FAD over the last few years is probably not going to meaningfully change in 2026.

[Juan Sanabria, Managing Director at BMO Capital Markets]

Okay. And then just Canada, a new market for you and, I think, your first investment in the long-term care there. So just curious if you could give us a little bit of a quick one-on-one on the Canadian market versus the U.S. I'm assuming it's more akin to U.S. skilled nursing and kind of what opportunity this new sleeve potentially represents for Omega.

[Matthew Gourmand, President at Omega Healthcare Investors]

Sure. I mean, as you can imagine, all of these things are, are pretty involved in detail. If you were going to give an analogy, I'd probably say it's closest to the U.K. care home market, more than the skilled nursing market, and the fact that, it's a little bit more of a socialized medicine system there, so they don't make people exhaust the financial options they do in the U.S.

[Matthew Gourmand, President at Omega Healthcare Investors]

At the same time, most people tend to be longer-term residents within those facilities. In terms of a little bit of a background on this, yeah, we're very excited about this opportunity. We had an opportunity to invest with a very well-established and high-quality developer and operator in the Canadian long-term care market that we've got to know over the last year.

[Matthew Gourmand, President at Omega Healthcare Investors]

We were able to structure a deal that we think can be sustainably accretive. However, I would say this is a little bit of an idiosyncratic investment. We wouldn't expect to significantly grow in the general Canadian senior housing market, as this is traditionally offered yields that are not particularly compelling to us, given our cost of capital. However, we would be open to continue to grow with this operator, assuming they can find deals that fit within the parameters of our cost of capital and are able to be accretive deals for us.

[Operator]

Our next question comes from the line of Farrell Granath from Bank of America. Please go ahead.

[Farrell Granath, Equity Research Associate at Bank of America]

Thank you and good morning. Similar, I guess, to that question, is thinking about the investment mix in 2026. We're just curious if what you've already closed in January of 2026 and early February is kind of in line of how we should be thinking of a mixture of loans, as well as triple net and SHOP.

[Vikas Gupta, CIO at Omega Healthcare Investors]

Yeah, I'll speak to the pipeline. I think that'll help you. If you just look at our pipeline, it is strong, as both Taylor and I said. It's in line with really where we closed 2025. And if you look at what's actionable, about a third is skilled nursing, a third is senior housing, and a third is U.K. care homes. As for structure, it's a mixed bag. I would say a lot of the U.K. and U.S. senior housing is RIDEA focused.

[Farrell Granath, Equity Research Associate at Bank of America]

Okay. Thank you. Also, just given recent headlines around the CMA investigating some peers for recent transactions in the UK, does that change any of your feelings on transactions in the UK or influence any of your investment decisions?

[Vikas Gupta, CIO at Omega Healthcare Investors]

Yeah, no, we are not concerned about that. Our lawyers do similar type of checks for us every time we would do a U.K. care home transaction. We've never, ever been in breach of anything or close to it. So from our perspective, we are not worried about growing in the U.K. right now.

[Farrell Granath, Equity Research Associate at Bank of America]

Okay. And just one small follow-up, also just on your dividend, if there's any additional updates on coverage or how you're thinking about your dividend?

[Taylor Pickett, CEO at Omega Healthcare Investors]

We're getting closer to needing to increase the dividend, but obviously it's a board call. And typically, we'll get to the point where we're required to increase our dividend from a tax perspective, and that's going to be in the low 80s from some FAD payout. That's how I would think about it.

[Farrell Granath, Equity Research Associate at Bank of America]

Okay. Thank you very much.

[Operator]

Our next question comes from the line of Michael Carroll from RBC Capital Markets. Please go ahead.

[Michael Carroll, Managing Director, Head of US Real Estate Research at RBC Capital Markets]

Yeah, thanks. I want to circle back on the Canadian loan. I want to make sure I understand this. So I guess the initial loan, your security is these five long-term care developments, but you have the option to convert it into the entire operator 35% stake in the entire operator?

[Matthew Gourmand, President at Omega Healthcare Investors]

So the collateral is actually over 20 long-term care homes that they currently own, that, as Victor said, is valued meaningfully more than the loan that we're looking to put out there, about twice the value of the loan that we're looking to put out there.

[Matthew Gourmand, President at Omega Healthcare Investors]

And yes, initially, the yields, it's in a loan structure to give us the yields that we're looking for. But to the extent that over time, the operating company is able to achieve yields similar to or above the yields we're achieving from a loan standpoint, we then have the optionality to flip that over, and based on our modeling, we would expect to be able to do that at some point during the term of the loan.

[Michael Carroll, Managing Director, Head of US Real Estate Research at RBC Capital Markets]

Okay. Can you give us an idea of what the equity stake would be, I guess, the yield on the equity stake today? And, and I'm assuming it's lower than the loan amount, I guess. And then how much growth is in the long-term care market? I mean, how fast could that yield grow? So if you do convert it into an equity stake, I mean, are we thinking about a mid-single-digit type growth rate, or is it potentially higher than that? Are they seeing the similar trends as we are in the U.S.?

[Matthew Gourmand, President at Omega Healthcare Investors]

Yeah, the initial yield today is lower than obviously our 10% yield on the debt. I don't honestly know exactly what the number is, Michael, but it's cash flow positive, and it's obviously got a lot of collateral behind it. To the extent of when we convert it over, it's gonna be somewhat contingent on whether there's continued opportunities to do these developments. It is nicely accretive, so I would say that mid-single-digit growth is on the conservative side of things. I think this could definitely be high single-digit or even double-digit growth, as they continue to develop.

[Matthew Gourmand, President at Omega Healthcare Investors]

There's a lot of need within the Canadian market right now, and this is a proven developer and operator that we think can meet a certain amount of the need that the Canadian people have in the Ontario market.

[Michael Carroll, Managing Director, Head of US Real Estate Research at RBC Capital Markets]

Yeah, great. Appreciate it.

[Matthew Gourmand, President at Omega Healthcare Investors]

Thanks.

[Operator]

Our next question comes from the line of Alec Feygin from Baird. Please go ahead.

[Alec Feygin, Equity Research Associate at Baird]

Hey, thanks for taking my question. So first for me would be: When you evaluated the development loan in Canada, how would that compare to maybe similar loans in the United States? And would you expect that to be a bigger part of the investment flow in 2026?

[Matthew Gourmand, President at Omega Healthcare Investors]

So it's very different. You know, in this situation, we had a lot of collateral sitting behind our loan. You know, a lot of the time when you're putting these loans out there, the collateral might just be the development deal itself, which has inherently more risk attached to it.

[Matthew Gourmand, President at Omega Healthcare Investors]

This also is a known entity that has proven an ability to develop at very, very consistent cost rates relative to budget over a prolonged period of time, which gave us increased comfort. And so to that point, I don't think this is something that we're gonna look to be doing. First of all, we're just not fans of loans generally. To the point we were making earlier, those loans tend to come back to you.

[Matthew Gourmand, President at Omega Healthcare Investors]

You know, this really is a little bit of a loan with a vehicle to have equity interest longer term, which is obviously something that we are more interested in. But the idea of loaning into development deals is probably not something we're gonna be looking to do.

[Alec Feygin, Equity Research Associate at Baird]

All right. That's helpful. And maybe, you know, now that you're in the RIDEA business, are you looking to convert any current senior housing in the portfolio to that structure?

[Matthew Gourmand, President at Omega Healthcare Investors]

You know, there's two forms of conversion here, right? There's the conversion out of necessity and the conversion out of opportunity. You know, you've seen a lot of people convert because ultimately there wasn't the capacity to pay the rents.

[Matthew Gourmand, President at Omega Healthcare Investors]

Where we sit today in our senior housing portfolio, obviously, we've talked about Maplewood being a RIDEA-like model, but outside of that, all of our operators are cash flowing sufficiently to continue to pay our rent, so there's no necessity to do that. But if there were opportunistic chances to take operating exposure at a yield that is compelling to us, either in the U.S. or the U.K., we'd obviously look to do that.

[Matthew Gourmand, President at Omega Healthcare Investors]

We understand that the nature of such operating exposure creates increased volatility, so we'd be looking for a fairly healthy yield, in order to do that, but it's not outside of the realm of possibility we'd look to do so.

[Alec Feygin, Equity Research Associate at Baird]

Okay, thank you.

[Operator]

Our next question comes from the line of John Pawlowski from Green Street. Please go ahead.

[John Pawlowski, Managing Director, Residential at Green Street]

Hey, thanks for the time. Matthew, first question on your guys' foray into RIDEA. It is a, I mean, it is a different skill set for a triple net credit investor framework from Omega of old, and just curious, what has had to change internally, either on the investment team or asset management team, to get ready for a more operationally intensive, tougher model to underwrite?

[Matthew Gourmand, President at Omega Healthcare Investors]

It's probably quicker to tell you what hasn't changed. You know, you're absolutely right, John. This is inherently a higher risk, potentially higher return model. We don't have that credit support sitting behind in the form of coverage, and therefore, I would say that we have looked at every element of this from the standpoint of the quality of the underwriting.

[Matthew Gourmand, President at Omega Healthcare Investors]

We've brought in new members of the team who have decades of experience within the senior housing business, who have a very deep bench of operators that they know, that they've worked with before. We've looked at every element of the P&L in terms of trying to understand why lower occupancy happens, what the differentiation of CapEx is between the asset classes, whether we want a first-tier market or second-tier market, looking at the demographics.

[Matthew Gourmand, President at Omega Healthcare Investors]

We have taken an extremely, what I think, thoughtful and intense approach to truly understand what the risks are around this, given the fact that there isn't that credit sitting behind us. We are still, I think, sufficiently conservative to understand that very much like the UK, it makes sense for us to dip our toe into this judiciously.

[Matthew Gourmand, President at Omega Healthcare Investors]

I wouldn't look for us to be doing a billion-dollar deal anytime soon, because we do think there's still more to learn. But as we've seen in the UK, the ability to deploy capital over the course of a decade for it to become not only a meaningful part of our business, but a highly accretive and valuable part of our business, I think we look at over the next decade, RIDEA being a similar opportunity.

[John Pawlowski, Managing Director, Residential at Green Street]

Okay. I appreciate all those thoughts. Megan, maybe a quick one for you. At the state level, are you hearing any concerning anecdotes or potential draft legislation for staffing mandates at the state level?

[Megan Krull, Senior Vice President, Data Intelligence and Government Relations at Omega Healthcare Investors]

No, nothing, nothing more than what we've heard in the past. So there's always, you know, rumblings, and there are, you know, states who are, you know, pushing the federal government to try to institute another staffing mandate, but we're not really hearing that across the board.

[John Pawlowski, Managing Director, Residential at Green Street]

Yeah. Thank you for the time.

[Operator]

Again, if you would like to ask a question, press star one on your telephone keypad. I will now turn the call back over to Taylor Pickett for closing remarks.

[Taylor C. Pickett, CEO at Omega Healthcare Investors]

Thanks. Thank you. Thanks, all, for joining our call today. As always, we're available for follow-up questions.

[Operator]

Ladies and gentlemen, that concludes today's call. Thank you all for joining. You may now disconnect.

Participants

Executives

• Bob Stephenson, CFO
• Matthew Gourmand, President
• Megan Krull, Senior Vice President, Data Intelligence and Government Relations
• Michele Reber, Head of Investor Relations
• Taylor C. Pickett, CEO
• Taylor Pickett, CEO
• Vikas Gupta, CIO

Analysts

• Alec Feygin, Equity Research Associate at Baird
• Elmer Chang, Equity Research Associate at Scotiabank
• Farrell Granath, Equity Research Associate at Bank of America
• John Kilichowski, Executive Director Equity Research at Wells Fargo
• John Pawlowski, Managing Director, Residential at Green Street
• Juan Sanabria, Managing Director at BMO Capital Markets
• Julien Blouin, Vice President, Real Estate Global Investment Research at Goldman Sachs
• Michael Carroll, Managing Director, Head of US Real Estate Research at RBC Capital Markets
• Michael Goldsmith, US REITs Analyst at UBS
• Nick Joseph, Head of US Real Estate and Lodging Research at Citi
• Omotayo Okusanya, Managing Director, Head of US REIT Research at Deutsche Bank